Skip to content

Rhinocerebral Mucormycosis in COVID-19 Patients.

Incidence and Screening for Rhinocerebral Mucormycosis and its risk factors in patients with COVID-19: A Multicentric Combined Retrospective and Prospective Cohort Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035670
Enrollment
500
Registered
2021-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B461- Rhinocerebral mucormycosis

Interventions

None listed

Sponsors

Dr Ujjwala Maheshwari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age 18 years of age and above with or without Diabetes Mellitus. 2) Participants diagnosed with covid-19 and being hospitalized and undergoing treatment for the same for the prospective group. 3) Participants who have been deemed clinically recovered from COVID 19 and discharged up to 28 days prior to the commencement of participant recruitment for the retrospective group

Exclusion criteria

Exclusion criteria: Participants who have succumbed to COVID-19 during the duration of study.

Design outcomes

Primary

MeasureTime frame
To screen for Rhino Cerebral Mucormycosis and study the incidence of the same in patients with COVID 19. Timepoint: To screen for Rhino Cerebral Mucormycosis and study the incidence of the same in patients with COVID 19 at 2 weeks, 4 weeks and 6 weeks after discharge.

Secondary

MeasureTime frame
To detect Rhino Cerebral Mucormycosis prior to the clinical onset of the disease in these cases using cytological, histopathological and microbiological methods. Timepoint: at 2 weeks, 4 weeks and 6 weeks after discharge.;To study Post covid cases for development of ROCM within 4 weeks of discharge from the hospitalTimepoint: at 2 weeks, 4 weeks and 6 weeks after discharge.;To study the correlation of Pharmacotherapy with Steroids, Immunomodulator drugs, Oxygen Supplementation and Antibiotics for COVID-19 with the relative risk of development of Rhino Cerebral Mucormycosis in these patients. Timepoint: at 2 weeks, 4 weeks and 6 weeks after discharge.;To study the incidence of Rhino Cerebral Mucormycosis in moderate to severe covid cases hospitalized for the management of COVID 19.Timepoint: at 2 weeks, 4 weeks and 6 weeks after discharge.

Countries

India

Contacts

Public ContactDr Usha Asnani

MGM Dental College and Hospital Navi Mumbai

srivalli.shrikanth@gmail.com9769088803

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026